General Information
Revision date
2004-03-10
Product name
Myfortic Tablets, 180 and 360 mg
Product Synonyms
Mycophenolic Acid Tablets
Chemical name
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4- methylhex-4-enoic acid salt
CAS No.
24280-93-1
Icons in SDS
Company Information
company name
NOVARTIS PHARMACEUTICALS CORPORATION
Section 2
SECTION 2: Hazards identification
EMERGENCY OVERVIEW *************************************************************************************************** FINISHED PHARMACEUTICAL PRODUCT REFER TO PHYSICIANS' DESK REFERENCE OR PACKAGE INSERT IMMUNOSUPPRESANT AGENT MAY CAUSE GASTROINTESTINAL DISORDERS MAY CAUSE INCREASED SUSCEPTIBILITY TO INFECTION MAY ADVERSELY AFFECT THE DEVELOPING FETUS ***************************************************************************************************
Principle Routes of Exposure
Oral EFFECTS OF OVEREXPOSURE: Finished pharmaceutical product. Potential for exposure is reduced in this form. Skin: No hazard is expected from normal clinical use. Eye: No hazard is expected from normal clinical use. Inhalation: No hazard is expected from normal clinical use. Ingestion: No hazard is expected from normal clinical use. THERAPEUTIC SIDE EFFECTS: Anemia, leucopenia, constipation, nausea, diarrhea, vomiting, urinary tract infection, and insomnia. TARGET ORGAN EFFECTS: Affects the blood and blood-forming organs. REPRODUCTIVE HAZARDS: Pregnancy Category C. Experimental reproductive effects have been reported. (see section 11). CARCINOGENICITY: Not carcinogenic. (see section 11). MUTAGENICITY: Positive in two in vitro assays and one in vivo assay; negative in two other in vitro assays. (see Section 11).
Medical Conditions Generally Aggravated by Exposure
Known hypersensitivity to Myfortic or any of its excipients